Humana (HUM) has seen a multitude of events impacting its business and share price. Announcing
Q4 2024 earnings release and
2025 financial guidance, it was subject to an
investigation initiated by a former Louisiana Attorney General. Despite some underperformance compared to competitors, the
price target for Humana was increased to
$290 from $260. Yet, due to growth versus rising costs, the firm is held by cautious investors. Significant purchases were made by
First Hawaiian Bank. However, Humana saw a decline in membership for its top-rated Medicare plans. Despite mixed news, including appointment of a new CIO to
lead digital transformation and the CFO transition, the firm's stock has been vulnerable with
Medicare ratings causing a plunge and merger talks with Cigna ending. Conversely, Humana reported
Q3 earnings beating estimates on rising premiums and cost management with its stock seen as a potential buy at 52-week lows.
Humana HUM News Analytics from Wed, 31 Jul 2024 07:00:00 GMT to Fri, 10 Jan 2025 22:44:00 GMT -
Rating -1
- Innovation -2
- Information 7
- Rumor -5
